🟠 Moderate Evidence
- The Prescribing Paradox: Why Viral Infections Get Antibiotics
- Biomarkers as a Clinical Compass: Separating Bacterial from Viral
- Implementation Barriers: Beyond the Test Result
- A Path Forward: Standardized Decision Pathways and Health Systems Integration
- Frequently asked questions
- How accurate is procalcitonin testing for distinguishing bacterial from viral respiratory infections?
- Will biomarker testing be available in resource-limited settings where antibiotic overuse is most common?
- Does biomarker-guided prescribing delay necessary antibiotic treatment for serious infections?
Antibiotic overuse in respiratory tract infections (RTIs) represents one of the most pressing antimicrobial resistance (AMR) challenges in global primary care, with particular urgency in high-consumption regions. A commentary published in The Lancet Respiratory Medicine examines whether combined biomarker testing could reshape prescribing practices and curb unnecessary antibiotic dispensing at the point of care.
Key takeaways
- Approximately 70–80% of respiratory tract infections in primary care are viral and self-limiting, yet antibiotics remain widely prescribed
- China alone accounts for roughly one quarter of global antibiotic consumption, with RTI management a major driver of unnecessary use
- Biomarker-guided testing strategies (including C-reactive protein, procalcitonin, and host-response markers) show promise in differentiating bacterial from viral infections
- Implementation barriers include cost, time constraints in busy clinics, and clinician familiarity with interpretation
- Standardized clinical decision pathways combining multiple biomarkers could optimize prescribing while maintaining patient safety
Global Antibiotic Consumption: Key Burden Regions
Estimated share of global antibiotic use by region, with respiratory infections a major driver in high-consumption countries
Source: The Lancet Respiratory Medicine commentary, 2026 | Georgian Medical Journal News
The Prescribing Paradox: Why Viral Infections Get Antibiotics
The fundamental clinical problem is straightforward yet persistent: most upper and lower respiratory tract infections presenting to primary care are viral in origin and resolve without intervention. Yet The Lancet Respiratory Medicine commentary notes that antibiotics continue to be prescribed at high rates despite this well-established epidemiology.
The drivers of this paradox are multifaceted. Time-pressured consultations in primary care often make it faster to prescribe than to explain why an antibiotic is not needed. Patient expectations—shaped by previous experience and cultural norms around antibiotic efficacy—create pressure on clinicians to provide a tangible treatment. Diagnostic uncertainty in the clinic setting, where rapid differentiation between viral and bacterial infection is difficult without laboratory confirmation, leads many practitioners to adopt a cautious, antibiotics-first approach.
The consequences are severe. According to the World Health Organization, antimicrobial resistance is already responsible for an estimated 1.27 million deaths per year globally and threatens to undermine progress in treating infectious diseases. In low- and middle-income settings, where surveillance is weaker and self-medication is more common, the problem is amplified.
Biomarkers as a Clinical Compass: Separating Bacterial from Viral
Biomarker-guided diagnostic strategies offer a potential solution by providing objective, rapid evidence at the point of care. C-reactive protein (CRP) and procalcitonin (PCT) have emerged as the most studied markers, with procalcitonin showing particular promise for bacterial-versus-viral discrimination in respiratory infections.
The logic is sound: bacterial infections typically trigger a more robust inflammatory cascade and higher procalcitonin elevation than uncomplicated viral infections. By setting clinical thresholds—for example, prescribing antibiotics only when PCT exceeds 0.25 ng/mL—clinicians can reduce unnecessary prescribing while retaining safety. Multiple randomized controlled trials have demonstrated that PCT-guided strategies reduce antibiotic use by 20–40% in acute respiratory infections without increasing adverse outcomes or treatment failures.
However, single-marker approaches have limitations. Host-response markers (such as pentraxin-3, neutrophil-to-lymphocyte ratios, and interferon-gamma signatures) are emerging as complementary diagnostics that may improve discrimination when used in combination. The commentary suggests that algorithmic combination of multiple biomarkers—rather than reliance on any single marker—may optimize both sensitivity and specificity.
Most upper and lower respiratory tract infections presenting to primary care are viral in origin and self-limiting, yet antibiotics continue to be prescribed at high rates. Combined biomarker strategies could provide objective evidence to guide prescribing decisions at the point of care.
— The Lancet Respiratory Medicine commentary, 2026
Implementation Barriers: Beyond the Test Result
Despite biomarker potential, real-world implementation faces substantial obstacles. Cost remains a barrier: procalcitonin assays and newer host-response tests are more expensive than clinical judgment alone, and reimbursement structures in many healthcare systems do not yet cover routine point-of-care biomarker testing in primary care.
Workflow integration is complex. Primary care clinics operate under severe time constraints, and point-of-care testing infrastructure (including rapid assay devices, quality assurance, and result interpretation) requires investment and training. Clinicians unfamiliar with biomarker cutoffs and their limitations may either over-interpret results or revert to habitual prescribing regardless of test findings.
Trust and familiarity gaps persist. Some primary care physicians remain skeptical of biomarker-guided approaches, particularly in regions where empiric treatment has been standard practice for decades. Health policy initiatives and continuing medical education will be essential to build confidence and standardize interpretation across diverse clinical settings.
A Path Forward: Standardized Decision Pathways and Health Systems Integration
The Lancet commentary suggests that the most promising approach combines three elements: (1) standardized clinical decision algorithms that integrate patient symptoms, vital signs, and biomarker results; (2) health system-level investment in point-of-care testing infrastructure and training; and (3) sustained antimicrobial stewardship programs that monitor prescribing trends and provide feedback to clinicians.
Countries with high antibiotic consumption—particularly China and other regions in South and Southeast Asia—are well-positioned to pilot integrated biomarker-guided programmes. The World Health Organization’s Global Action Plan on Antimicrobial Resistance emphasizes the need for diagnostic stewardship as a cornerstone of AMR mitigation, and biomarker integration aligns directly with this agenda.
Success will require collaboration between primary care networks, diagnostic manufacturers, health technology assessment bodies, and policymakers. Early adopter programmes in high-burden regions could generate real-world evidence on cost-effectiveness and clinical outcomes, building the case for broader implementation and reimbursement.
What this means
Frequently asked questions
How accurate is procalcitonin testing for distinguishing bacterial from viral respiratory infections?
Procalcitonin shows good discrimination when bacterial and viral infections are clearly separated, but many infections present with overlapping features. Sensitivity and specificity typically range from 70–90%, depending on the clinical setting and cutoff threshold chosen. Combination with other markers (CRP, host-response signatures) improves accuracy.
Will biomarker testing be available in resource-limited settings where antibiotic overuse is most common?
Currently, availability is limited. Point-of-care biomarker devices exist, but cost and infrastructure barriers remain high in low- and middle-income countries. WHO and international funding bodies are prioritizing diagnostic stewardship in high-burden regions, but widespread rollout will require sustained investment and policy support.
Does biomarker-guided prescribing delay necessary antibiotic treatment for serious infections?
Large randomized trials have shown that PCT-guided algorithms do not increase adverse outcomes or mortality compared to standard care, even when antibiotics are delayed in low-risk patients. However, implementation requires clear clinical pathways to ensure that patients with signs of severe or progressive infection receive prompt treatment regardless of biomarker results.
As antimicrobial resistance continues to threaten global health security, the clinical and public health case for biomarker-guided prescribing grows stronger. The next phase of implementation will test whether health systems—particularly in high-antibiotic-consumption regions—can translate this evidence into routine primary care practice. Success will require not just better diagnostics, but coordinated investment in infrastructure, training, and supportive reimbursement policy. The opportunity to reshape antibiotic prescribing at scale exists now; realizing it depends on health systems acting with the same urgency they bring to other critical safety priorities.
Source: Can combined biomarker testing shape the future of primary care antibiotic prescribing? — The Lancet Respiratory Medicine, 2026
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
